Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Millennium Research

Neither a doctor nor a teaching hospital

Research payments

$1,731,180

452 payments

Through program year 2025, Millennium Research is reported as receiving $1,731,180 in research payments, across 452 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $32,286 3
2024 Research $121,588 118
2023 Research $178,587 136
2022 Research $673,492 66
2021 Research $161,586 44
2020 Research $151,436 39
2019 Research $412,205 46

Breakdown

Who paid Research payments · program years 2019–2025
  1. AbbVie, Inc. $931,094 180 payments
  2. Novartis Pharmaceuticals Corporation $490,359 1 payment
  3. E.R. Squibb & Sons, L.L.C. $152,570 12 payments
  4. Kiniksa Pharmaceuticals, Ltd. $97,165 144 payments
  5. Kiniksa Pharmaceuticals International, plc $30,582 110 payments
  6. Amgen Inc. $15,413 3 payments
  7. Pfizer Inc. $12,946 1 payment
  8. Ucb SA $1,051 1 payment
Studies the money was for Research payments · program years 2019–2025
  1. A Post-Trial Access Roll-Over Study to Allow Access to Ribociclib (Lee011) for Patients Who Are on Ribociclib Treatment in Novartis-Sponsored Study $490,359 1 payment
  2. Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 18 to 75 Years of Age Treated With Subcutaneous (SC) Injections of ABBV-154 for Moderately to Severely Active Rheumatoid Arthritis (RA) $176,868 20 payments
  3. M15-572 $150,581 21 payments
  4. M15-554 $136,056 21 payments
  5. A Phase 2, Multicenter, Randomized, Double-blind, Placebo Controlled Study to Assess the Safety, Pharmacokinetics, and Efficacy of KPL-404 in Subjects With Moderate to Severe Active Rheumatoid Arthritis With Inadequate Response or Intolerance to at Least One Biologic Disease-modifying Anti-rheumatic Drug or a Janus Kinase Inhibitor $115,493 240 payments
  6. M13-545 $110,753 16 payments
  7. M15-998 $98,511 14 payments
  8. A Study Evaluating the Efficacy and Safety of Afimetoran Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (SLE) $91,594 2 payments
  9. A Phase 2 Study to Investigate the Safety and Efficacy of Elsubrutinib and Upadacitinib Given Alone or in Combination (ABBV-599 Combination) in Subjects with Moderately to Severely Active Systemic Lupus Erythematosus $47,208 4 payments
  10. A Phase 3, Randomized, Double-Blind Study Comparing Risankizumab to Placebo in Subjects with Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or intolerance to Biologic Therapy(ies) (KEEPsAKE 2) $26,056 8 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record